2 research outputs found

    Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVIDā€19 vaccine: A singleā€center prospective observational study (NCT05074706)

    No full text
    Abstract Hematological patients at higher risk of severe COVIDā€19 were excluded from the severe acute respiratory syndrome coronavirus 2 (SARSā€CoVā€2) vaccine trials. In this singleā€center observational prospective study (NCT05074706), we evaluate immune response in the hematological patients followed at the Hematological Division of San Gerardo Hospital, Monza (Italy) deemed to be severely immunosuppressed after vaccination with two doses of the BNT162b2 vaccine. Antiā€SARSā€CoVā€2 immunoglobulin G titers above the cutoff value of 33.8 BAU/ml were detected in 303 (80.2%) out of the 378 patients enrolled. Patients with lymphoproliferative disorders had a significant lower probability of immunization (43.2% vs. 88.4%, pĀ <Ā 0.001). Patients treated with antiā€CD20 showed a significantly lower probability of immunization compared to all other treatments (21.4%, pĀ <Ā 0.0001). Among 69 patients who failed seroconversion, 15 patients (22.7%) showed a positive Tā€cell response. Patients previously treated with antiā€CD20 were 2.4 times more likely to test positive for Tā€cell responses (pĀ =Ā 0.014). Within a followā€up of 9 months from the second COVIDā€19 vaccination, symptomatic SARSā€CoVā€2 infections were reported by 20 patients (5.3%) and four of them required hospitalization. Successful serological or Tā€cellā€mediated immunization conferred protection from symptomatic COVIDā€19. Patients treated with antiā€CD20 who were not seroconverted after vaccination might still be protected from COVIDā€19 due to the Tā€cell immune response
    corecore